Cleveland-based drug development accelerator BioMotiv is teaming up with Atomwise Inc., which uses artificial intelligence to help discover new medicine, on what they describe as a “strategic collaboration to co-develop therapies.”
The organizations on Monday, Jan. 13, announced in a news release that they will “form co-owned, joint development companies that will integrate Atomwise’s AI technology and BioMotiv’s deep expertise in preclinical and clinical development to translate innovative academic and early-stage research into small-molecule therapies.”
Click here to read the complete article.
Story excerpt provided by Crain’s Cleveland Business.
Written by Scott Suttell.
Originally published January 13, 2020.